Structure-Activity Relationship Study of Majusculamide D: Overcoming Metabolic Instability and Severe Toxicity with a Fluoro Analogue
Majusculamide D, isolated from the marine cyanobacterium <i>Moorea producens</i>, is an anticancer lipopentapeptide consisting of fatty acid, tripeptide, and pyrrolyl proline moieties. In this work, by utilizing a convergent synthetic approach, late-stage modification, and bioisostere strategy, 26 majusculamide D analogues were synthesized, and two (<b>1i</b> and <b>1j</b>) demonstrated IC<sub>50</sub> values < 1 nM against PANC-1 cancer cells. The results summarized a preliminary structure-activity relationship mainly at the C23, C4, C34, and C10 sites. A series of in vitro assays, including wound healing, transwell, clone formation, EdU, and western blot, confirmed that majusculamide D inhibited the migration, invasion, and proliferation of pancreatic cancer cells. The optimized fluorinated analogue <b>1n</b> demonstrated a notable enhancement in stability during the mouse plasma assay (>50% left after 24 h), exhibited tumor-suppressive effects (51.5% at a dosage of 5 mg/kg), and successfully mitigated the severe toxicity (no mouse dead) observed in the group treated with majusculamide D (3 mice dead) in a xenografted mouse model.
Authors
- Mengxue Lv
- Xiuhe Zhao
- Mingxiao Zhang (ORCID: https://orcid.org/0000-0002-4903-2025)
- Xiaonan Xi
- Yue Chen (ORCID: https://orcid.org/0000-0001-8888-1452)
- Liang Wang (ORCID: https://orcid.org/0000-0001-9132-6222)
- Xiang Zhang (ORCID: https://orcid.org/0000-0001-7317-4253)
- Yaxin Lu
Institutions
- Nankai University (CN)
- Unité Matériaux et Transformations (FR)
Publication Details
- Journal
- Marine Drugs
- Published
- 2024-11-29
- DOI
- https://doi.org/10.3390/md22120537
- Citations
- 5
- Primary Topic
- Microbial Natural Products and Biosynthesis
- Type
- article
- Field-Weighted Citation Impact
- 2.24
Funders
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Nankai University
- Fundamental Research Funds for the Central Universities